Buchang Pharmaceutical has started a buy-buy-buy model, and plans to acquire Beijing Siheyuan across the border this time!

Buchang Pharmaceuticals has formulated "switching from a sales company to a technology company", "switching from proprietary Chinese medicines to biologics, vaccines, chemicals, medical devices, and Internet medicine" since 2018, and "switching from Chinese localization to globalization" Since these three major transformation strategies, the mode of buying, buying and buying has been started
.
Since 2021, the pace of Buchang Pharmaceutical's mergers and acquisitions is still accelerating
.
According to the 2021 semi-annual report, Buchang Pharmaceuticals invested in the establishment of Buchang Tao Yiyun Health Technology (Hangzhou) Co.
, Ltd.
and Shangzhi Buchang Biomedical Technology Co.
, Ltd.
in the first half of 2021; plans to invest in Jiangxi Buchang Mobile Medical Equipment Co.
, Ltd.
, Shangzhi step mobile medical equipment Limited
.
In August of the same year, it invested in the establishment of Ningbo Zhishan Zechen Health Technology Co.
, Ltd.
, and in September invested in the establishment of a wholly-owned subsidiary Shaanxi Xianyang Shunfa Co.
, Ltd.
, and subsequently invested in the establishment of Ningbo Buchang Trading Company, acquisition of Hunan Zhongce, etc.
Recently, Buchang Pharmaceutical also announced that the company and its wholly-owned subsidiary, Shenzhou Pharmaceutical, intends to acquire 100% of Beijing Chengrui's equity for 271 million yuan
.
According to data, Beijing Chengrui was established on September 21, 2020.
Financial data shows that as of August 31, 2021, Beijing Chengrui has total assets of 221 million yuan, total liabilities of 256 million yuan, and net assets of -34,652,100 yuan in 2021.
The operating income from January to August is 0 yuan, and the net profit from January to August 2021 is -35,642,100 yuan
.
The announcement shows that this acquisition is to meet the future business development needs of Buchang Pharmaceuticals, promote the smooth implementation of the company's overall strategy, enhance the company's overall operating environment and external image, and realize the plan of "China's Johnson & Johnson, the world's step"
.
This acquisition can form a platform for cooperation and exchange of Chinese medicine culture
.
But for this new company with a loss of tens of millions of yuan, Buchang Pharmaceuticals attracted the attention of investors after the announcement of the acquisition and received an inquiry letter from the Shanghai Stock Exchange. .
The Shanghai Stock Exchange requires companies to supplementally disclose the main business conditions, main business models, main products (if any), main assets, etc.
of the target assets; supplementary disclosure of the main financial indicators since the establishment of the target assets, including but not limited to total assets, total liabilities, and net assets , Operating income, net profit before and after deduction, etc.
; combined with the company's future development strategy, target asset operation and financial situation, further explain the purpose, reason and rationality of this acquisition
.
On October 22, Buchang Pharmaceutical issued an announcement regarding the Shanghai Stock Exchange’s reply to the inquiry letter of the company’s external acquisitions, which further explained the purpose, reasons and rationality of the acquisition
.
The company stated that the acquisition of Beijing Chengrui was to acquire a historic courtyard house located in Beijing's core urban area under its name.
The property has a superior geographical location and a rich history
.
This acquisition of the company will help the company build a Chinese medicine culture platform on this basis.
The company plans to build a Chinese medicine culture museum to facilitate the company's promotion of Chinese medicine culture and business activities and academic exchange activities
.
In addition, Buchang Pharmaceutical stated that this acquisition is of great significance to the company's publicity of Chinese medicine culture, and it is in line with the company's development strategy and development goals, is conducive to the company's further development in the future, and is necessary for the acquisition
.
This acquisition is conducive to the realization of the company's overall strategic goals, improves the company's overall operating environment, and meets market needs.
The company's main business will not change as a result
.
The company's business is in good condition, and this acquisition will not adversely affect the company's financial status and operating results
.